Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus

Basit Öğe Kaydı
dc.contributor.authorIcli, Abdullah
dc.contributor.authorCure, Erkan
dc.contributor.authorCure, Medine Cumhur
dc.contributor.authorUslu, Ali Ugur
dc.contributor.authorBalta, Sevket
dc.contributor.authorMikhailidis, Dimitri P.
dc.contributor.authorOzturk, Cengiz
dc.date.accessioned2024-02-23T14:26:48Z
dc.date.available2024-02-23T14:26:48Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractSystemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. A major cause of morbidity and mortality in SLE is accelerated atherosclerosis. Endothelial-specific molecule 1 (endocan) is a potential predictor of vascular events and is expressed in response to inflammatory cytokines in endothelial cells. We investigated the relationship between endocan and carotid intima-media thickness (cIMT) as a marker of early atherosclerosis. We included 44 women with SLE and 44 healthy women as controls. Disease severity of SLE was evaluated using the SLE Disease Activity Index. Endocan, C-reactive protein, erythrocyte sedimentation rate (ESR), and lipid panel were measured. The cIMT was 0.70 (range: 0.45-1.20) mm in patients with SLE and 0.40 (0.25-0.60) mm in controls (P < .001). Endocan value was 1.6 +/- 0.9 ng/mL in controls and 2.2 +/- 1.0 ng/mL in patients with SLE (P = .014). Endocan levels were positively correlated with cIMT (r = .469, P < .001), body mass index (r = .373, P = .013), and ESR (r = .393, P = .008). Endocan level may be associated with subclinical atherosclerosis in SLE. Consequently, endocan levels may be a promising clinical tool for patients with SLE as a guide for preventive strategy.en_US
dc.description.sponsorshipMSD; AstraZeneca; Libytecen_US
dc.description.sponsorshipThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DPM has given talks and attended conferences sponsored by MSD, AstraZeneca and Libytec.en_US
dc.identifier.doi10.1177/0003319715616240
dc.identifier.endpage755en_US
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.issue8en_US
dc.identifier.pmid26614790en_US
dc.identifier.scopus2-s2.0-84983081943en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage749en_US
dc.identifier.urihttps://doi.org/10.1177/0003319715616240
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14340
dc.identifier.volume67en_US
dc.identifier.wosWOS:000382857900007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofAngiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndocanen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.subjectAtherosclerosisen_US
dc.subjectInflammationen_US
dc.titleEndocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu